Stella Pharma Corporation (TYO:4888)

Stella Pharma Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	3,801	2,823	3,206	2,052	2,710	3,276
Short-Term Investments	-	-	-	300	-	-
Cash & Short-Term Investments	3,801	2,823	3,206	2,352	2,710	3,276
Cash Growth	33.41%	-11.95%	36.31%	-13.21%	-17.28%	161.87%
Accounts Receivable	101	67	714	76	59	16
Receivables	101	67	714	76	59	16
Inventory	1,205	1,295	1,230	1,116	940	773
Prepaid Expenses	77	66	49	40	39	36
Other Current Assets	70	102	44	45	44	74
Total Current Assets	5,254	4,353	5,243	3,629	3,792	4,175
Property, Plant & Equipment	46	47	66	81	102	92
Long-Term Investments	51	43	57	57	371	382
Other Intangible Assets	40	42	49	52	61	68
Other Long-Term Assets	1	1	2	1	3	1
Total Assets	5,392	4,486	5,417	3,820	4,329	4,718

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	1	-	22	75	49	48
Accrued Expenses	8	8	7	4	6	2
Current Portion of Long-Term Debt	158	158	158	160	160	160
Current Income Taxes Payable	54	83	197	212	202	92
Other Current Liabilities	19	10	6	4	4	6
Total Current Liabilities	240	259	390	455	421	308
Long-Term Debt	740	588	608	773	933	1,093
Pension & Post-Retirement Benefits	60	59	59	53	47	51
Other Long-Term Liabilities	1,135	1,154	1,153	163	176	187
Total Liabilities	2,175	2,060	2,210	1,444	1,577	1,639

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	3,365	2,859	2,859	2,938	3,300	3,808
Additional Paid-In Capital	854	348	489	195	220	1,908
Retained Earnings	-1,009	-780	-140	-763	-778	-2,636
Comprehensive Income & Other	7	-1	-1	6	10	-1
Shareholders' Equity	3,217	2,426	3,207	2,376	2,752	3,079
Total Liabilities & Equity	5,392	4,486	5,417	3,820	4,329	4,718

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	898	746	766	933	1,093	1,253
Net Cash (Debt)	2,903	2,077	2,440	1,419	1,617	2,023
Net Cash Growth	36.74%	-14.88%	71.95%	-12.25%	-20.07%	-
Net Cash Per Share	84.75	61.05	73.10	45.81	56.00	72.04
Filing Date Shares Outstanding	34.95	34.02	34.02	31.22	29.48	28.65
Total Common Shares Outstanding	34.95	34.02	34.02	31.22	29.48	28.65
Working Capital	5,014	4,094	4,853	3,174	3,371	3,867
Book Value Per Share	92.04	71.31	94.27	76.10	93.35	107.48
Tangible Book Value	3,177	2,384	3,158	2,324	2,691	3,011
Tangible Book Value Per Share	90.89	70.07	92.83	74.43	91.28	105.10

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 24, 2026

Data Sources Report a data error